RESUMO
Leprosy caused by Mycobacterium leprae primarily affects the skin and peripheral nerves. As a human infectious disease, it is still a significant health and economic burden on developing countries. Although multidrug therapy is reducing the number of active cases to approximately 0.5 million, the number of cases per year is not declining. Therefore, alternative host-directed strategies should be addressed to improve treatment efficacy and outcome. In this work, using murine leprosy as a model, a very similar granulomatous skin lesion to human leprosy, we have found that successive IFN-alpha boosting protects BCG-vaccinated mice against M. lepraemurium infection. No difference in the seric isotype and all IgG subclasses measured, neither in the TH1 nor in the TH2 type cytokine production, was seen. However, an enhanced iNOS/NO production in BCG-vaccinated/i.m. IFN-alpha boosted mice was observed. The data provided in this study suggest a promising use for IFN-alpha boosting as a new prophylactic alternative to be explored in human leprosy by targeting host innate cell response.
Assuntos
Vacina BCG/uso terapêutico , Interferon-alfa/uso terapêutico , Infecções por Mycobacterium/tratamento farmacológico , Infecções por Mycobacterium/prevenção & controle , Mycobacterium lepraemurium , Animais , Vacina BCG/administração & dosagem , Injeções Intramusculares , Interferon-alfa/administração & dosagem , CamundongosRESUMO
Follicular lymphoma is the most common type of primary cutaneous B-cell lymphomas with a predilection for the scalp, forehead, and trunk. Herein we report a case of primary cutaneous follicle center lymphoma on the scalp of 72-year-old female. The diagnosis was made histopathologically, confirming the presence of centrocytes and centroblasts. Complete resolution was achieved following administration of subcutaneous interferon α-2a at a dose of 4.5 × 106 IU three times weekly for 3 months.
Assuntos
Neoplasias de Cabeça e Pescoço/tratamento farmacológico , Fatores Imunológicos/uso terapêutico , Interferon-alfa/uso terapêutico , Linfoma Folicular/tratamento farmacológico , Couro Cabeludo , Neoplasias Cutâneas/tratamento farmacológico , Idoso , Feminino , Neoplasias de Cabeça e Pescoço/patologia , Humanos , Interferon alfa-2 , Linfoma Folicular/patologia , Proteínas Recombinantes/uso terapêutico , Couro Cabeludo/patologia , Neoplasias Cutâneas/patologiaAssuntos
Infecções por Herpesviridae/imunologia , Herpesvirus Humano 8/imunologia , Sarcoma de Kaposi/virologia , Neoplasias Cutâneas/virologia , Antígenos Virais de Tumores , Antivirais/uso terapêutico , Criança , Soronegatividade para HIV , Infecções por Herpesviridae/complicações , Humanos , Interferon-alfa/uso terapêutico , Masculino , Sarcoma de Kaposi/tratamento farmacológico , Sarcoma de Kaposi/imunologia , Neoplasias Cutâneas/tratamento farmacológico , Neoplasias Cutâneas/imunologiaRESUMO
En los últimos años la inmunoterapia ha tomado un gran auge debido, primordialmente, a la variedad de alternativas descritas, fundamentadas en una gran cantidad de estudios clínicos, lo que ha permitido que enfermedades aparentemente poco complicadas, pero cuya resolución es frecuentemente problemática, como las infecciones recurrentes de las vías respiratorias, hasta enfermedades crónicas como tuberculosis, lepra, colagenopatías y enfermedades malignas, etc., ahora puedan tener un mejor pronostico. Es importante resaltar la importancia de conocer las características farmacologicas de estos medicamentos, así como sus indicaciones precisas. con el fin de no caer en el mal uso de los mismos y poder ofrecer a los pacientes un recurso valioso y eficaz de cara al nuevo milenio
Assuntos
Humanos , Pediatria , Doenças Respiratórias , Imunidade Celular/imunologia , Imunoterapia , Adjuvantes Imunológicos/administração & dosagem , Adjuvantes Imunológicos/química , Adjuvantes Imunológicos/uso terapêutico , Formação de Anticorpos/imunologia , Terapêutica , Interferon-alfa/metabolismo , Interferon-alfa/uso terapêutico , Relação Dose-Resposta ImunológicaRESUMO
AIDS: Certain HIV drugs have significant side effects. There have been reports from Europe that some hemophiliacs using protease inhibitors suffered from spontaneous bleeding. Clofazimine, sold as Lamprene, has been shown to cause harm when used with clarithromycin and ethambutol to treat MAC. Lamprene may cause internal bleeding, nausea, diarrhea, dizziness, drowsiness, and dry skin. Results of a Taiwanese trial of thymosin-alpha indicate that it did not help treat Hepatitis B in a statistically significant way. NAC, an antioxidant, may increase glutathione levels and indirectly increase survival.^ieng